Reuters logo
5 个月前
BRIEF-Ignyta announces peer-reviewed publication of activity of a TRK inhibitor
2017年3月30日 / 上午11点22分 / 5 个月前

BRIEF-Ignyta announces peer-reviewed publication of activity of a TRK inhibitor

March 30 (Reuters) - Ignyta Inc

* Ignyta announces peer-reviewed publication of activity of a TRK inhibitor in a primary brain tumor: successful treatment of glioneuronal tumor with pan-TRK, CNS-active inhibitor Entrectinib published in precision oncology

* Study found three NTRK fusions within cohort of 26 glioneuronal tumors

* 1 patient with NTRK1 fusion was treated with Entrectinib, resulting in 60 pct tumor regression, resolution of clinical symptoms

* In study, patient received Entrectinib daily for 11 months and experienced lower extremity edema as only documented side effect related to therapy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below